Abstract
Vaginal trichomoniasis is a sexually transmitted disease of worldwide importance that is commonly treated with metronidazole. Although surprisingly uncommon, resistance to metronidazole has nevertheless been widely reported. Patients with suspected resistant trichomoniasis should have the diagnosis confirmed either by visualization of motile trichomonads on saline microscopy or by culture. In addition, reinfection from a partner must be ruled out through a careful history. Data regarding treatment of metronidazole-resistant trichomoniasis are mainly limited to case reports or series. Most cases can be treated successfully with increasing doses of oral metronidazole. Other promising options include oral tinidazole and topical paromomycin cream.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Petrin D, Delgaty K, Bhait R, Garber G: Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998, 11:300–317. Very thorough basic science and clinical overview of infections caused by T. vaginalis.
Lossick JG, Kent HL: Trichomoniasis: trends in diagnosis and management. Am J Obstet Gynecol 1991, 165:1217–1222.
Cotch MF, Pastorek JG, Nugent RP, et al.: Vaginal Infections and Prematurity Study Group: demographic and behavioral predictors of Trichomonas vaginalis infection among pregnant women. Obstet Gynecol 1991, 78:1087–1092.
Krieger JN, Tam MR, Stevens CE, et al.: Diagnosis of trichomoniasis: comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. JAMA 1988, 259:1223–1238.
Pastorek JG, Cotch MF, Martin DH, Eschenbach DA: Vaginal Infections and Prematurity Study Group: clinical and microbiological correlates of vaginal trichomoniasis during pregnancy. Clin Infect Dis 1996, 23:1075–1080.
Centers for Disease Control and Prevention: 1998 Guidelines for treatment of sexually transmitted diseases. MMWR 1998, 47:74–75. The latest Centers for Disease Control and Prevention recommendations for the management of trichomoniasis
Burtin P, Taddio A, Ariburnu O, et al.: Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995, 72:525–529.
Krieger JN: Trichomoniasis in men: old issues and new data. Sex Transm Dis 1995, 22:83–96.
Krieger JN, Verdon M, Siegel N, Holmes KK: Natural history of urogenital trichomoniasis in men. J Urol 1993, 149:1455–1458.
Müller M, Lossick JG, Gorrell TE: In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Transm Dis 1988, 15:17–24.
Lossick JG, Müller M, Gorrell TE: In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis 1986, 153:948–955.
Dombrowski MP, Sokol RJ, Brown WJ, Bronsteen RA:Intravenous therapy of metronidazole-resistant Trichomonas vaginalis. Obstet Gynecol 1987, 69:524–525.
Dan M, Sobel JD: Trichomoniasis as seen in a chronic vaginitis clinic. Infect Dis Obstet Gynecol 1996, 4:77–84.
Houang ET, Ahmet Z, Lawrence AG: Successful treatment of four patients with recalcitrant vaginal trichomoniasis with a combination of zinc sulfate douche and metronidazole therapy. Sex Transm Dis 1997, 24:116–119.
Sears SD, O’Hare J: In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrob Agents Chemother 1988, 32:144–146.
Pattman RS, Sprott MS, Kearns AM, Earnshaw M: Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports. Genitourin Med 1989, 65:274–275.
Wong CA, Wilson PD, Chew TA: Povidone-iodine in the treatment of metronidazole-resistant Trichomonas vaginalis. Aust N Z J Obstet Gynaecol 1990, 30:169–171.
Livengood CH III, Lossick JG: Resolution of resistant vaginal trichomoniasis associated with the use of intravaginal nonoxynol-9. Obstet Gynecol 1991, 78:954–956.
British Co-Operative Clinical Group: An investigation, by questionnaire, of cases of recalcitrant vaginal trichomoniasis seen in genitourinary medicine clinics in the United Kingdom. Int J STD AIDS 1992, 3:24–27.
Voolman T, Boreham P: Metronidazole resistant Trichomonas vaginalis in Brisbane. Med J Aust 1993, 159:490.
Hamed KA, Studemeister AE: Successful response of metronidazole-resistant trichomonal vaginitis to tinidazole. Sex Transm Dis 1992, 19:339–340.
Nyirjesy P, Weitz MV, Gelone SP, Fekete T: Paromomycin for nitroimidazole-resistant trichomonosis. Lancet 1995, 346:1110.
Nyirjesy P, Sobel JD, Weitz MV, et al.: Difficult to treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 1998, 26:986–988. Case series reviewing experience with paromomycin cream in cases in which metronidazole resistance or allergy was present
Spitzbart H: Ist Paromomycin zur Behandlung der Trichomonaden-Infecktion bei der Frau geeignet? II: Klin Erfahrungen. Zentralbl Gynakol 1966, 88:563–566.
Pearlman MD, Yashar C, Ernst S, Solomon W: An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reactions to metronidazole. Am J Obstet Gynecol 1996, 174:934–936.
Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB:Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991, 88:279–280.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nyirjesy, P. Managing resistant Trichomonas vaginitis. Curr Infect Dis Rep 1, 389–392 (1999). https://doi.org/10.1007/s11908-999-0047-x
Issue Date:
DOI: https://doi.org/10.1007/s11908-999-0047-x